Embleema and George Washington University-led Consortium Wins FDA Contract to Advance the Fight Against Infectious Disease Outbreaks
Retrieved on:
Thursday, October 28, 2021
University, Data Management, Education, Technology, FDA, Health, General Health, Research, Infectious Diseases, Software, Science, George Washington University, Research, Molecular medicine, Ecosystem, Database, Vaccine, DRS, Genomics, Crandall, FDA, Temple University, Food, Pandemic, Severe acute respiratory syndrome coronavirus 2, Simonyan, CEO, ARGOS, GW, Microbiology, Biochemistry, Therapy, Weatherall Institute of Molecular Medicine, Pharmaceutical industry, Medical device
Embleema, a New Jersey-based healthcare technology company, has partnered with investigators at The George Washington University (GW) and Temple University (TU) to advance the Food and Drug Administrations (FDA) Database for Reference Grade Microbial Sequences (FDA-ARGOS).
Key Points:
- Embleema, a New Jersey-based healthcare technology company, has partnered with investigators at The George Washington University (GW) and Temple University (TU) to advance the Food and Drug Administrations (FDA) Database for Reference Grade Microbial Sequences (FDA-ARGOS).
- Embleema was awarded a contract worth $1,992,223 by the FDA for the development of quality matrix tools for FDA-ARGOS containing regulatory grade reference genomes for diagnostic use and regulatory science.
- It is also clear that regulators need a sustainable, evolving ARGOS ecosystem that can be continuously enriched with novel information on existing and emerging pathogens.
- Embleemas standard technology platform accelerates personalized medicine by expediting evidence generation and regulatory reviews of new treatments.